ReNeuron Group Plc (RENE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ReNeuron Group Plc (RENE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10128
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The company’s therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. ReNeuron utilizes its exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered “off-the-shelf” to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc (RENE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
Licensing Agreements 14
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
Equity Offering 15
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc – Key Competitors 21
ReNeuron Group Plc – Key Employees 22
ReNeuron Group Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 12, 2018: ReNeuron: Preliminary results for the year ended 31 March 2018 24
Dec 14, 2017: ReNeuron Group: Interim Results for the six months ended 30 September 2017 30
Jun 29, 2017: ReNeuron Group: Preliminary Results for the Year Ended 31 March 2017 33
Corporate Communications 34
Apr 10, 2018: ReNeuron: Appointment of US-based Chief Medical Officer 34
Apr 10, 2018: Appointment Of US-Based Chief Medical Officer 35
Sep 01, 2017: ReNeuron Group: Non-executive Director Appointment 36
Jul 19, 2017: ReNeuron Group: Board change 37
Government and Public Interest 38
Apr 19, 2018: ReNeuron: Wins grant for retinal cell therapy development 38
May 11, 2017: ReNeuron awarded major UK cell therapy manufacturing grant 39
Jan 23, 2017: Merck Announces Emerging Biotech Grant Program Winners 40
Product News 41
11/08/2017: ReNeuron Group: Retinal disease clinical trial moves into Phase II 41
06/19/2017: FDA approves cryopreserved formulation of ReNeurons retinal stem cell therapy candidate 42
05/05/2017: ReNeuron presents new data with its exosome therapy programme at major scientific conference 43
04/19/2018: ReNeuron wins grant for retinal cell therapy development 44
Mar 26, 2018: ReNeuron Group: Product Development Update 45
Clinical Trials 47
May 04, 2018: ReNeuron Group: Exosome data presented at ISCT conference 47
Feb 13, 2018: ReNeuron Group: Positive pre-clinical data in nerve injury 48
Jan 26, 2018: ReNeuron: Phase II stroke data presented at AHA conference 49
Dec 14, 2017: ReNeuron Group: Stroke Clinical Trial Regulatory Approval in US 50
Oct 31, 2017: ReNeuron Group: Positive stroke clinical data & regulatory update 51
Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 52
Jun 05, 2017: ReNeuron progresses clinical and regulatory strategy for the US with stroke programme based on positive FDA regulatory feedback 53
May 18, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference 54
Apr 21, 2017: ReNeuron advances global clinical development strategy with cell therapy candidate for stroke disability 55
Other Significant Developments 56
Sep 19, 2018: ReNeuron Group provides business development update 56
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 57
Apr 21, 2017: ReNeuron successfully develops cryopreserved formulation of its retinal stem cell therapy candidate and expands ophthalmology programmes 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReNeuron Enters into Research Agreement with Benitec Biopharma 12
ReNeuron Enters Into Co-Development Agreement With Cell Therapy Catapult 13
ReNeuron Enters into Licensing Agreement with US-Based Pharma Company 14
ReNeuron Raises USD105 Million in Private Placement of Shares 15
ReNeuron Raises USD25.4 Million in Private Placement of Shares 16
ReNeuron Group Completes Private Placement Of Shares For US$8.7 Million 17
ReNeuron Group Completes Rights Offering Of Shares For US$1 Million 19
ReNeuron Group Plc, Key Competitors 21
ReNeuron Group Plc, Key Employees 22
ReNeuron Group Plc, Subsidiaries 23

List of Figures
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReNeuron Group Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ReNeuron Group Plc (RENE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Celsion Corp (CLSN)-医療機器分野:企業M&A・提携分析
    Summary Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (L …
  • The Emirates Group:企業の戦略・SWOT・財務分析
    The Emirates Group - Strategy, SWOT and Corporate Finance Report Summary The Emirates Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Telekom Malaysia Berhad (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Berhad (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • The Interpublic Group of Companies, Inc.:企業の戦略・SWOT・財務分析
    The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Interpublic Group of Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Sing Investments & Finance Ltd (S35):企業の財務・戦略的SWOT分析
    Sing Investments & Finance Ltd (S35) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Whirlpool Corporation (WHR):企業の財務・戦略的SWOT分析
    Whirlpool Corporation (WHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Ilmarinen Mutual Pension Insurance Co-エネルギー分野:企業M&A・提携分析
    Summary Ilmarinen Mutual Pension Insurance Company (IMPIC) is a financial service provider that offers pension insurance and related services. The company provides services for private customers, which include information on pensions, retiring, pensioner, forms and brochures, pensioner's tax card, a …
  • Nexen Energy ULC:石油・ガス:M&Aディール及び事業提携情報
    Summary Nexen Energy ULC (Nexen Energy), formerly Nexen Inc., a subsidiary of CNOOC Limited, is an upstream oil and gas company that discovers and develops energy resources. It is involved in the production of conventional oil and gas, oil sands, and shale gas. The company’s activities include explo …
  • Gentex Corporation:企業の戦略・SWOT・財務情報
    Gentex Corporation - Strategy, SWOT and Corporate Finance Report Summary Gentex Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Edmond De Rothschild (Suisse) S.A.
    Edmond De Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report Summary Edmond De Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • EVN AG:発電所・企業SWOT分析
    EVN AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • Tom N Toms Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tom N Toms Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Orion Diagnostica Oy:医療機器:M&Aディール及び事業提携情報
    Summary Orion Diagnostica Oy (Orion Diagnostica), a subsidiary of Orion Oyj, is a medical equipment company that develops, manufactures clinical diagnostic and hygiene monitoring tests. Its product portfolio provides diagnosis and treatment management kits, point of care systems, ready to use kits, …
  • Immunogen, Inc.:企業の戦略・SWOT・財務分析
    Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Immunogen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • WEC Energy Group Inc (WEC):電力:M&Aディール及び事業提携情報
    Summary WEC Energy Group, Inc. (WEC) is a diversified holding company that carries out the generation and distribution of electricity in southeastern Wisconsin, east central Wisconsin, northern Wisconsin, and Michigan's Upper Peninsula; and transports and distributes natural gas in the upper peninsu …
  • CSX Corporation, Inc.:戦略・SWOT・企業財務分析
    CSX Corporation, Inc. - Strategy, SWOT and Corporate Finance Report Summary CSX Corporation, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • 3D Signatures Inc (DXD):医療機器:M&Aディール及び事業提携情報
    Summary 3D Signatures Inc (3D Signatures) is a developer of diagnostic and prognostic products for cancers and neurological disorders. The company's pipeline products include 3D Telo-PC a tool that is used to treat prostate cancer. It also provides 3D Telo-RS a diagnostic and prognostic tool used fo …
  • Boehringer Ingelheim GmbH:企業の戦略・SWOT・財務分析
    Boehringer Ingelheim GmbH - Strategy, SWOT and Corporate Finance Report Summary Boehringer Ingelheim GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • PageGroup plc (PAGE):企業の財務・戦略的SWOT分析
    PageGroup plc (PAGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • University of British Columbia-製薬・医療分野:企業M&A・提携分析
    Summary University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its stude …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆